Comparative efficacy of biologics is an important consideration when selecting therapies for Crohn’s disease (CD). While recent studies have focused on clinical remission, few studies have assessed the comparative efficacy of biologics in preventing penetrating disease (PD) complications of CD. The aim of our study was to compare the rates of penetrating complications (luminal and perianal) between biologics used as first-line therapies in CD.